TY - JOUR
T1 - Deep phenotyping of health–disease continuum in the Human Phenotype Project
AU - Reicher, Lee
AU - Shilo, Smadar
AU - Godneva, Anastasia
AU - Lutsker, Guy
AU - Zahavi, Liron
AU - Shoer, Saar
AU - Krongauz, David
AU - Rein, Michal
AU - Kohn, Sarah
AU - Segev, Tomer
AU - Schlesinger, Yishay
AU - Barak, Daniel
AU - Levine, Zachary
AU - Keshet, Ayya
AU - Shaulitch, Rotem
AU - Lotan-Pompan, Maya
AU - Elkan, Matan
AU - Talmor-Barkan, Yeela
AU - Aviv, Yaron
AU - Dadiani, Maya
AU - Tsodyks, Yonatan
AU - Gal-Yam, Einav Nili
AU - Leibovitzh, Haim
AU - Werner, Lael
AU - Tzadok, Roie
AU - Maharshak, Nitsan
AU - Koga, Shin
AU - Glick-Gorman, Yulia
AU - Stossel, Chani
AU - Raitses-Gurevich, Maria
AU - Golan, Talia
AU - Dhir, Raja
AU - Reisner, Yotam
AU - Weinberger, Adina
AU - Rossman, Hagai
AU - Song, Le
AU - Xing, Eric P.
AU - Segal, Eran
N1 - Publisher Copyright:
© The Author(s), under exclusive licence to Springer Nature America, Inc. 2025.
PY - 2025/9
Y1 - 2025/9
N2 - The Human Phenotype Project (HPP) is a large-scale deep-phenotype prospective cohort. To date, approximately 28,000 participants have enrolled, with more than 13,000 completing their initial visit. The project is aimed at identifying novel molecular signatures with diagnostic, prognostic and therapeutic value, and at developing artificial intelligence (AI)-based predictive models for disease onset and progression. The HPP includes longitudinal profiling encompassing medical history, lifestyle and nutrition, anthropometrics, blood tests, continuous glucose and sleep monitoring, imaging and multi-omics data, including genetics, transcriptomics, microbiome (gut, vaginal and oral), metabolomics and immune profiling. Analysis of these data highlights the variation of phenotypes with age and ethnicity and unravels molecular signatures of disease by comparison with matched healthy controls. Leveraging extensive dietary and lifestyle data, we identify associations between lifestyle factors and health outcomes. Finally, we present a multi-modal foundation AI model, trained using self-supervised learning on diet and continuous-glucose-monitoring data, that outperforms existing methods in predicting disease onset. This framework can be extended to integrate other modalities and act as a personalized digital twin. In summary, we present a deeply phenotyped cohort that serves as a platform for advancing biomarker discovery, enabling the development of multi-modal AI models and personalized medicine approaches.
AB - The Human Phenotype Project (HPP) is a large-scale deep-phenotype prospective cohort. To date, approximately 28,000 participants have enrolled, with more than 13,000 completing their initial visit. The project is aimed at identifying novel molecular signatures with diagnostic, prognostic and therapeutic value, and at developing artificial intelligence (AI)-based predictive models for disease onset and progression. The HPP includes longitudinal profiling encompassing medical history, lifestyle and nutrition, anthropometrics, blood tests, continuous glucose and sleep monitoring, imaging and multi-omics data, including genetics, transcriptomics, microbiome (gut, vaginal and oral), metabolomics and immune profiling. Analysis of these data highlights the variation of phenotypes with age and ethnicity and unravels molecular signatures of disease by comparison with matched healthy controls. Leveraging extensive dietary and lifestyle data, we identify associations between lifestyle factors and health outcomes. Finally, we present a multi-modal foundation AI model, trained using self-supervised learning on diet and continuous-glucose-monitoring data, that outperforms existing methods in predicting disease onset. This framework can be extended to integrate other modalities and act as a personalized digital twin. In summary, we present a deeply phenotyped cohort that serves as a platform for advancing biomarker discovery, enabling the development of multi-modal AI models and personalized medicine approaches.
UR - https://www.scopus.com/pages/publications/105010943399
U2 - 10.1038/s41591-025-03790-9
DO - 10.1038/s41591-025-03790-9
M3 - Article
C2 - 40665053
AN - SCOPUS:105010943399
SN - 1078-8956
VL - 31
SP - 3191
EP - 3203
JO - Nature Medicine
JF - Nature Medicine
IS - 9
ER -